Sun Lan, Huangfu Liwei, Li Fang, Yan Yuhui, Kong Ruiping, Ji Kun, Li Jiachun
Department of Pharmaceutical Engineering, Jiangsu Food and Pharmaceutical Science College, Huaian, Jiangsu, China.
State Key Laboratory of New-tech For Chinese Medicine Pharmaceutic Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, Jiangsu, China.
Front Oncol. 2025 Feb 18;15:1532602. doi: 10.3389/fonc.2025.1532602. eCollection 2025.
Colorectal cancer (CRC), characterized by its complex genetic heterogeneity and varied responses to treatment, is a leading cause of cancer-related mortality worldwide. The role of N1-methyladenosine (m1A)-related genes in tumor biology remains underexplored. This study aimed to investigate the prognostic value of m1A-related genes in CRC, characterize their role in tumor molecular subtyping, and explore their influence on the tumor microenvironment (TME) and immune infiltration.
To identify prognostic markers, univariate Cox analysis was performed using multiple datasets, including TCGA and GEO, identifying 43 m1A-related genes. Four distinct molecular subtypes of CRC were defined based on the expression of these genes using non-negative matrix factorization (NMF). Immune infiltration analysis was conducted, and the TIDE algorithm was used to predict response to immune checkpoint inhibitors (ICIs). Furthermore, a prognostic model based on m1A-related genes was constructed and validated across multiple datasets.
The results demonstrated that the four CRC molecular subtypes exhibited significant differences in survival outcomes and clinical characteristics. Stromal cells showed higher m1A scores, suggesting a regulatory role in the TME. There was a positive correlation between m1A-related gene expression and immune checkpoint genes. Moreover, the constructed prognostic model showed robust predictive performance and outperformed other recently published models.
The findings suggest that m1A-related genes are not only valuable biomarkers for CRC prognosis but also have significant implications for the immune landscape and could serve as potential targets for therapeutic intervention, particularly in the context of immunotherapy. For instance, SLC12A2 was found to enhance invasion, proliferation, and migration of colorectal cancer cells while inhibiting apoptosis. Further studies are needed to understand the functional roles of m1A modifications across different cell types within the TME.
结直肠癌(CRC)具有复杂的基因异质性和对治疗的不同反应,是全球癌症相关死亡的主要原因。N1-甲基腺苷(m1A)相关基因在肿瘤生物学中的作用仍未得到充分探索。本研究旨在探讨m1A相关基因在CRC中的预后价值,阐明其在肿瘤分子亚型中的作用,并探索其对肿瘤微环境(TME)和免疫浸润的影响。
为了识别预后标志物,使用包括TCGA和GEO在内的多个数据集进行单变量Cox分析,鉴定出43个m1A相关基因。基于这些基因的表达,使用非负矩阵分解(NMF)定义了四种不同的CRC分子亚型。进行了免疫浸润分析,并使用TIDE算法预测对免疫检查点抑制剂(ICI)的反应。此外,构建了基于m1A相关基因的预后模型,并在多个数据集上进行了验证。
结果表明,四种CRC分子亚型在生存结果和临床特征方面存在显著差异。基质细胞显示出较高的m1A评分,表明其在TME中具有调节作用。m1A相关基因表达与免疫检查点基因之间存在正相关。此外,构建的预后模型显示出强大的预测性能,优于其他最近发表的模型。
研究结果表明,m1A相关基因不仅是CRC预后的有价值生物标志物,而且对免疫格局具有重要意义,可作为治疗干预的潜在靶点,特别是在免疫治疗方面。例如,发现SLC12A2可增强结肠癌细胞的侵袭、增殖和迁移,同时抑制细胞凋亡。需要进一步研究以了解m1A修饰在TME内不同细胞类型中的功能作用。